Synecta in future CAR-T programs

This market research assesses how additional clinical superiority data for Synecta-based CAR manufacturing would change buying behavior and tests acceptance of competitive repopulation data.

Compared with CD3/CD28 beads, Synecta has shown immune synapse formation, more balanced T-cell metabolism, improved cell killing in several preclinical models, and increased persistence in a clinical trial. We now want to test in a controlled clinical study whether Synecta activation and expansion confer superiority in CAR-T fitness in cancer patients.

Competitive repopulation means two cell populations in one patient

Each patient’s cells are used to make two comparable CAR-T products, one with Synecta and one with CD3/CD28 beads. Equal numbers are mixed and infused into the same patient. Tracking both populations over approximately six months shows which persists better under the same conditions.

19 questions, shown one at a time. Open-text answers are optional.

Scroll to Top
Equal numbers of Synecta-expanded and CD3/CD28 bead-expanded CAR-T cells are infused into one patient. An illustrative assumed result shows Synecta cells increasing in relative share over six months. The graph contains no measured data.

Assume a positive study result

Assume that Synecta-expanded cells outcompeted the control at around the six-month time point, with statistical significance, and the results have been published in a top-tier journal. Assume we used an AB/BA cross-over design to exclude any theoretical effects of the vector barcode. Further assume that GMP Synecta is available at current activation-reagent costs plus the value of replaced materials, such as cytokines. Also assume that absolute cell yields and manufacturing feasibility are at least as good as with your current technology, and that Synecta allows some simplification of the workflow.

Open-text answers are optional and may be left blank. Please complete the applicable choice questions and scales. The final follow-up section is optional.

Consider the three years after the assumed results become available.

3. What percentage of your planned new Phase 1 trials would use Synecta?

Choose the nearest 10%. Use the same planned trials in both scenarios. “Not sure” and “No trials planned” are also available.

Synecta T1 presents CD86, a natural ligand that can engage both the stimulatory receptor CD28 and the inhibitory receptor CTLA-4. This differs from direct stimulation with anti-CD28 antibodies. Whether this distinction provides a clinical safety advantage remains to be established.